

PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF

ACCESSION NO: 0002XB029468

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO : DRAWN :19/02/2024 08:44:16
RECEIVED :19/02/2024 08:45:41
REPORTED :20/02/2024 17:54:14

:35 Years

AGE/SEX

Test Report Status <u>Final</u> Results Biological Reference Interval Units

#### MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

602 b, behind dindoshi depot, dindoshi, malad east

**XRAY-CHEST** 

Mumbai 400097

IMPRESSION NO ABNORMALITY DETECTED

**ECG** 

ECG WITHIN NORMAL LIMITS

**MEDICAL HISTORY** 

RELEVANT PRESENT HISTORY

ALLERGIC RHINITIS

RELEVANT PAST HISTORY

TYPHOID 5 YRS BACK

DENGUE 1 YRS BACK. RENAL CALCULI 2012 NOT SIGNIFICANT

MENSTRUAL HISTORY (FOR FEMALES) REGULAR

LMP (FOR FEMALES) 29/1/2024

RELEVANT FAMILY HISTORY HEART DISEASE / DIABETES / CANCER

HISTORY OF MEDICATIONS NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

RELEVANT PERSONAL HISTORY

HEIGHT IN METERS 1.48 mts
WEIGHT IN KGS. 72 Kgs
BMI 33 BMI & Weight Status as follows/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal

25.0 - 29.9: Overweight 30.0 and Above: Obese

**GENERAL EXAMINATION** 

MENTAL / EMOTIONAL STATE NORMAL

German

MD, DNB, DMRD

Diring

Dr. J N Shukla ,MBBS, AFIH Consultant Physician





Page 1 Of 27

View Details

View Report



Dr. Swati Karmarkar,

**Consultant Radiologist** 

Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India





PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF

ACCESSION NO: **0002XB029468** AGE/SEX: 35 Years Female

602 b, behind dindoshi depot, dindoshi, malad east

CLIENT PATIENT ID: ABHA NO : RECEIVED : 19/02/2024 08:45:41

:19/02/2024 08:44:16

: REPORTED :20/02/2024 17:54:14

Test Report Status Final Results Biological Reference Interval Units

GENERAL APPEARANCE / NUTRITIONAL HEALTHY

**STATUS** 

Mumbai 400097

BUILT / SKELETAL FRAMEWORK AVERAGE
FACIAL APPEARANCE NORMAL
SKIN NORMAL
UPPER LIMB NORMAL
LOWER LIMB NORMAL

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

THYROID GLAND NOT ENLARGED

CAROTID PULSATION NORMAL TEMPERATURE NORMAL

PULSE 84/MIN.REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID

BRUIT

RESPIRATORY RATE NORMAL

**CARDIOVASCULAR SYSTEM** 

BP 120/84 MM HG mm/Hg

(SUPINE) NORMAL

APEX BEAT NORMAL HEART SOUNDS NORMAL MURMURS ABSENT

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST NORMAL MOVEMENTS OF CHEST SYMMETRICAL

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS ABSENT

**PER ABDOMEN** 

Securere

Dr. Swati Karmarkar, MD,DNB,DMRD Consultant Radiologist Theret

Dr. J N Shukla ,MBBS, AFIH Consultant Physician





Page 2 Of 27

View Details

View Report



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India





Female

**PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF** 

> ACCESSION NO: 0002XB029468 AGE/SEX

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO

:19/02/2024 08:44:16 DRAWN RECEIVED: 19/02/2024 08:45:41 REPORTED :20/02/2024 17:54:14

:35 Years

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

**NORMAL APPEARANCE** 

602 b, behind dindoshi depot, dindoshi, malad east

**NOT PALPABLE LIVER NOT PALPABLE SPLEEN NORMAL HERNIA** 

#### CENTRAL NERVOUS SYSTEM

**NORMAL** HIGHER FUNCTIONS CRANIAL NERVES **NORMAL NORMAL** CEREBELLAR FUNCTIONS SENSORY SYSTEM **NORMAL NORMAL** MOTOR SYSTEM **REFLEXES NORMAL** 

# **MUSCULOSKELETAL SYSTEM**

**NORMAL** SPINE **NORMAL** JOINTS

# **BASIC EYE EXAMINATION**

**NORMAL** CONJUNCTIVA **NORMAL EYELIDS** EYE MOVEMENTS NORMAL **CORNEA NORMAL** 

DISTANT VISION RIGHT EYE WITHOUT WITHIN NORMAL LIMIT (6/6)

**GLASSES** 

DISTANT VISION LEFT EYE WITHOUT REDUCE VISUAL ACUITY (6/9)

**GLASSES** 

NEAR VISION RIGHT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT (N6) WITHIN NORMAL LIMIT (N6) NEAR VISION LEFT EYE WITHOUT GLASSES

COLOUR VISION NORMAL (17/17)

MD, DNB, DMRD

Dr. J N Shukla , MBBS, AFIH **Consultant Physician** 





Page 3 Of 27

View Report



Dr. Swati Karmarkar,

**Consultant Radiologist** 

Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062 Maharashtra, India





Female

PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF

ACCESSION NO: 0002XB029468 AGE/SEX

602 b, behind dindoshi depot, dindoshi, malad east

CLIENT PATIENT ID: ABHA NO : DRAWN :19/02/2024 08:44:16
RECEIVED :19/02/2024 08:45:41
REPORTED :20/02/2024 17:54:14

:35 Years

Test Report Status <u>Final</u> Results Biological Reference Interval Units

#### **BASIC ENT EXAMINATION**

EXTERNAL EAR CANAL NORMAL TYMPANIC MEMBRANE NORMAL

NOSE NO ABNORMALITY DETECTED

SINUSES CLEAR

THROAT NO ABNORMALITY DETECTED

TONSILS NOT ENLARGED

#### **SUMMARY**

RELEVANT HISTORY NOT SIGNIFICANT RELEVANT GP EXAMINATION FINDINGS NOT SIGNIFICANT

RELEVANT LAB INVESTIGATIONS LOW HAEMOGLOBIN (11.8)
RAISED WBC COUNT (10.75)

RAISED HBA1C (5.8) RAISED EAG (119.8)

RAISED LDL CHOLESTEROL (112) RAISED TOTAL PROTEIN (8.7)

RELEVANT NON PATHOLOGY DIAGNOSTICS NO ABNORMALITIES DETECTED

REMARKS / RECOMMENDATIONS LOW HAEMOGLOBIN, RAISED WBC, RAISED ESR, RAISED LIVER

ENZYMES, RAISED HBA1C

MONITOR BLOOD SUGAR REGULARLY

ADV.VITAMIN D/B12

FOLLOW UP WITH PHYSICIAN FOR? INFECTION WITH RAISED LIVER

ENZYMES

Summered

Dr. Swati Karmarkar, MD,DNB,DMRD Consultant Radiologist



Dr. J N Shukla ,MBBS, AFIH Consultant Physician





Page 4 Of 27

iew Details

View Report



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India





:19/02/2024 08:44:16

PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF

ACCESSION NO: **0002XB029468** AGE/SEX: 35 Years Female

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: RECEIVED : 19/02/2024 08:45:41
ABHA NO : REPORTED : 20/02/2024 17:54:14

Test Report Status Final Results Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

602 b, behind dindoshi depot, dindoshi, malad east

**ULTRASOUND ABDOMEN** 

**ULTRASOUND ABDOMEN** 

NO ABNORMALITIES DETECTED

TMT OR ECHO
CLINICAL PROFILE

Mumbai 400097

NEGATIVE

Interpretation(s)

Summeren

Dr. Swati Karmarkar, MD,DNB,DMRD Consultant Radiologist Theret

Dr. J N Shukla ,MBBS, AFIH Consultant Physician





Page 5 Of 27

View Details

View Report



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India







PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF

ACCESSION NO: **0002XB029468** AGE/SEX: 35 Years

602 b, behind dindoshi depot, dindoshi, malad east

Mumbai 400097

CLIENT PATIENT ID: ABHA NO : DRAWN :19/02/2024 08:44:16
RECEIVED :19/02/2024 08:45:41
REPORTED :20/02/2024 17:54:14

Test Report Status Final Results Biological Reference Interval Units

1			
	IAEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECKUP BI BLOOD COUNTS,EDTA WHOLE BLOOD	ELOW 40FEMALE		
HEMOGLOBIN (HB)  METHOD: CYANIDE FREE DETERMINATION	11.8 Low	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT  METHOD: FLUORESCENCE FLOW CYTOMETRY	5.17 High	3.8 - 4.8	mil/μL
WHITE BLOOD CELL (WBC) COUNT METHOD: ELECTRICAL IMPEDANCE	10.75 High	4.0 - 10.0	thou/µL
PLATELET COUNT  METHOD: ELECTRONIC IMPEDENCE & MICROSCOPY	375	150 - 410	thou/μL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)  METHOD: CALCULATED PARAMETER	37.6	36 - 46	%
MEAN CORPUSCULAR VOLUME (MCV)  METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM	72.7 Low	83.0 - 101.0	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)  METHOD: CALCULATED PARAMETER	22.8 Low	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER	31.4 Low	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM	15.8 High	11.6 - 14.0	%
MENTZER INDEX	14.1		
MEAN PLATELET VOLUME (MPV)  METHOD: DERIVED PARAMETER FROM PLATELET HISTOGRAM	12.4 High	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS  METHOD: FLUORESCENCE FLOW CYTOMETRY	58	40 - 80	%
LYMPHOCYTES	33	20 - 40	%
METHOD: FLUORESCENCE FLOW CYTOMETRY MONOCYTES	4	2 - 10	%

In theme

Dr. Sushant Chikane Consultant Pathologist Healestee

Dr. Akshaya Mandloi,MD,PDF Consultant Hematopathologist and Head, Dept.of Hematopathology and Flowcytometry







Page 6 Of 27

View Details

View Report



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India



602 b, behind dindoshi depot, dindoshi, malad east





Female

PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF

ACCESSION NO: **0002XB029468** AGE/SEX: 35 Years

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO : DRAWN :19/02/2024 08:44:16
RECEIVED :19/02/2024 08:45:41
REPORTED :20/02/2024 17:54:14

Test Report Status <u>Final</u>	Results	Biological Reference	e Interval Units
METHOD: FLUORESCENCE FLOW CYTOMETRY			
EOSINOPHILS	5	1 - 6	%
METHOD: FLUORESCENCE FLOW CYTOMETRY			
BASOPHILS	0	0 - 1	%
METHOD: FLUORESCENCE FLOW CYTOMETRY			
ABSOLUTE NEUTROPHIL COUNT	6.24	2.0 - 7.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE LYMPHOCYTE COUNT	3.55 High	1.0 - 3.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE MONOCYTE COUNT	0.43	0.2 - 1.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE EOSINOPHIL COUNT	0.54 High	0.02 - 0.50	thou/µL
METHOD : CALCULATED PARAMETER	_		
ABSOLUTE BASOPHIL COUNT	0.00 Low	0.02 - 0.10	thou/µL
METHOD : CALCULATED PARAMETER			
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.8		
METHOD : CALCULATED	-		
ABSOLUTE NEUTROPHIL COUNT METHOD: CALCULATED PARAMETER ABSOLUTE LYMPHOCYTE COUNT METHOD: CALCULATED PARAMETER ABSOLUTE MONOCYTE COUNT METHOD: CALCULATED PARAMETER ABSOLUTE EOSINOPHIL COUNT METHOD: CALCULATED PARAMETER ABSOLUTE BASOPHIL COUNT METHOD: CALCULATED PARAMETER ABSOLUTE BASOPHIL COUNT METHOD: CALCULATED PARAMETER NEUTROPHIL LYMPHOCYTE RATIO (NLR)	3.55 High 0.43 0.54 High	1.0 - 3.0 0.2 - 1.0 0.02 - 0.50	thou/μL thou/μL thou/μL

# MORPHOLOGY

RBC Mild anisopoikilocytosis. Microcytic hypochromic with elliptocytes and

ovalocytes.

WBC Normal morphology.

PLATELETS Adequate in smear.

### Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Sushant Chikane Consultant Pathologist Hairentee

Dr. Akshaya Mandloi,MD,PDF Consultant Hematopathologist and Head, Dept.of Hematopathology and Flowcytometry





Page 7 Of 27

View Details

View Report



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India







**REF. DOCTOR: SELF PATIENT NAME: LIPIKA MISHRA** 

> ACCESSION NO: 0002XB029468 AGE/SEX :35 Years Female

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO

:19/02/2024 08:44:16 DRAWN RECEIVED: 19/02/2024 08:45:41

REPORTED :20/02/2024 17:54:14

**Test Report Status** Results **Biological Reference Interval** Units **Final** 

#### **HAEMATOLOGY**

#### MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

# **ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD**

602 b, behind dindoshi depot, dindoshi, malad east

21 High mm at 1 hr E.S.R = or < 12

METHOD: MODIFIED WESTERGREN METHOD BY AUTOMATED ANALYSER

# GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD**

Non-diabetic Adult < 5.7 HBA1C 5.8 High %

Pre-diabetes 5.7 - 6.4

Diabetes diagnosis: > or = 6.5Therapeutic goals: < 7.0 Action suggested: > 8.0

(ADA Guideline 2021)

METHOD: ION-EXCHANGE HPLC

ESTIMATED AVERAGE GLUCOSE(EAG) 119.8 High mg/dL < 116

# Comments

Advised: Kindly correlate clinically.

### Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD-**TEST DESCRIPTION**:Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sédimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are réported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

# TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis)

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibringen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,



Dr. Akshaya Mandloi, MD, PDF **Consultant Hematopathologist** and Head, Dept.of Hematopathology and Flowcytometry

Dr. Sushant Chikane **Consultant Pathologist** 





Page 8 Of 27

View Report



Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062 Maharashtra, India







**REF. DOCTOR: SELF PATIENT NAME: LIPIKA MISHRA** 

> ACCESSION NO: 0002XB029468 AGE/SEX

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO

:19/02/2024 08:44:16 DRAWN RECEIVED: 19/02/2024 08:45:41

:35 Years

REPORTED :20/02/2024 17:54:14

**Test Report Status** Results **Biological Reference Interval** <u>Final</u> Units

salicylates)

Mumbai 400097

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes

602 b, behind dindoshi depot, dindoshi, malad east

3. Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range. 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

- eAG gives an evaluation of blood glucose levels for the last couple of months.
   eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c 46.7

# HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

  3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr. Akshaya Mandloi, MD, PDF **Consultant Hematopathologist** and Head, Dept.of Hematopathology and Flowcytometry

Dr. Sushant Chikane **Consultant Pathologist** 





Page 9 Of 27

View Report



Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062 Maharashtra, India





AGE/SEX



Female

**PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF** 

ACCESSION NO: 0002XB029468

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO

DRAWN :19/02/2024 08:44:16 RECEIVED: 19/02/2024 08:45:41 REPORTED :20/02/2024 17:54:14

:35 Years

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

## **IMMUNOHAEMATOLOGY**

# MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

602 b, behind dindoshi depot, dindoshi, malad east

**ABO GROUP** В

METHOD: HAEMAGGLUTINATION (AUTOMATED)

**POSITIVE** RH TYPE

METHOD: HAEMAGGLUTINATION (AUTOMATED)

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

Dr. Sushant Chikane **Consultant Pathologist** 

Dr. Akshaya Mandloi, MD, PDF **Consultant Hematopathologist** and Head, **Dept.of Hematopathology and** Flowcytometry



Page 10 Of 27

View Report



Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

CIN - U74899PB1995PLC045956



Maharashtra, India Tel: 9111591115, Fax:



AGE/SEX



Female

PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF

602 b, behind dindoshi depot, dindoshi, malad east

Mumbai 400097

ACCESSION NO: **0002XB029468**PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO : DRAWN :19/02/2024 08:44:16
RECEIVED :19/02/2024 08:45:41
REPORTED :20/02/2024 17:54:14

:35 Years

Test Report Status <u>Final</u> Results Biological Reference Interval Units

# **BIOCHEMISTRY**


# MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR)

96

Normal <100 mg/dL Impaired fasting glucose:100 to 125 Diabetes mellitus: > = 126 (on more than 1 occassion) (ADA guidelines 2021)

METHOD: SPECTROPHOTOMETRY HEXOKINASE



**GLUCOSE, POST-PRANDIAL, PLASMA** 

PPBS(POST PRANDIAL BLOOD SUGAR)

102

Normal <140 mg/dL Impaired glucose tolerance:140 to 199 Diabetes mellitus : > = 200

(on more than 1 occassion) ADA guideline 2021

METHOD: SPECTROPHOTOMETRY HEXOKINASE



Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist



Dr. Deepak Sanghavi,M.D(Path) (Reg.no.MMC2004/03/1530) Chief of Mumbai Reference Lab.





Page 11 Of 27

View Details

View Report



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India







**PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF** 

> ACCESSION NO: 0002XB029468 AGE/SEX :35 Years

602 b, behind dindoshi depot, dindoshi, malad east

Mumbai 400097

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO

DRAWN :19/02/2024 08:44:16 RECEIVED: 19/02/2024 08:45:41

REPORTED :20/02/2024 17:54:14

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

LIPID PROFILE WITH CALCULATED LDL

CHOLESTEROL, TOTAL 182 Desirable: < 200 mg/dL

> Borderline: 200 - 239 High: > / = 240

METHOD: SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - CHOLETSEROL OXIDASE, ESTERASE, PEROXIDASE

TRIGLYCERIDES 124 Normal: < 150 mg/dL

Borderline high: 150 - 199

High: 200 - 499 Very High: >/= 500

METHOD: SPECTROPHOTOMETRY, ENZYMATIC ENDPOINT WITH GLYCEROL BLANK

mg/dL HDL CHOLESTEROL 45 At Risk: < 40

Desirable: > or = 60

METHOD: SPECTROPHOTOMETRY, HOMOGENEOUS DIRECT ENZYMATIC COLORIMETRIC

112 High mg/dL CHOLESTEROL LDL Optimal : < 100

Near optimal/above optimal:

100-129

Borderline high: 130-159

High: 160-189 Very high: = 190

METHOD: CALCULATED PARAMETER

137 High mg/dL Desirable: < 130 NON HDL CHOLESTEROL

> Above Desirable: 130 -159 Borderline High: 160 - 189

High: 190 - 219 Very high: >/=220

METHOD: CALCULATED PARAMETER

< or = 30.0VERY LOW DENSITY LIPOPROTEIN 25.0 mg/dL

METHOD: CALCULATED PARAMETER

CHOL/HDL RATIO 4.0 Low Risk: 3.3 - 4.4

Average Risk: 4.5 - 7.0 Moderate Risk: 7.1 - 11.0

High Risk : > 11.0

METHOD: CALCULATED PARAMETER

2.5 LDL/HDL RATIO Desirable/Low Risk: 0.5 - 3.0

Borderline/Moderate Risk: 3.1

- 6.0

High Risk: > 6.0

METHOD: CALCULATED PARAMETER

Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) **Consultant Pathologist** 



Dr. Deepak Sanghavi, M.D (Path) (Reg.no.MMC2004/03/1530) Chief of Mumbai Reference Lab.





Page 12 Of 27

View Report



Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062 Maharashtra, India



602 b, behind dindoshi depot, dindoshi, malad east



AGE/SEX



Female

PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF

ACCESSION NO: 0002XB029468

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO : DRAWN :19/02/2024 08:44:16 RECEIVED :19/02/2024 08:45:41

:35 Years

REPORTED :20/02/2024 17:54:14

Test Report Status <u>Final</u> Results Biological Reference Interval Units

# Interpretation(s)

Mumbai 400097

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

	ribe vib primeroscierone em diovinscumir di		
Risk Category			
Extreme risk group	A.CAD with > 1 feature of high risk group	A.CAD with > 1 feature of high risk group	
	B. CAD with > 1 feature of Very high risk g	group or recurrent ACS (within 1 year) despite LDL-C < or =	
	50 mg/dl or polyvascular disease		
Very High Risk	1. Established ASCVD 2. Diabetes with 2 r	major risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemia	a	
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ		
"	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary		
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Ath	Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors		
1. Age > or = 45 year	Age > or = 45 years in males and > or = 55 years in females     Current Cigarette smoking or tobacco use		
	Family history of premature ASCVD     4. High blood pressure		
5. Low HDL			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Treatment Goals Consider Drug Therapy		herapy
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/df)	
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80	
	< OR = 30)	<or 60)<="" =="" td=""><td></td><td></td></or>			
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or></td></or>	<or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or>	> 30	>60	
Very High Risk	<50	<80	>OR= 50	>OR= 80	
High Risk	<70	<100	>OR= 70	>OR= 100	
Moderate Risk	<100	<130	>OR= 100	>OR= 130	
Low Risk	<100	<130	>OR= 130*	>OR= 160	

<sup>\*</sup>After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

# LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.56	Upto 1.2	mg/dL
METHOD: SPECTROPHOTOMETRY, COLORIMETRIC -DIAZO	METHOD		
BILIRUBIN, DIRECT	0.20	< or = 0.3	mg/dL
METHOD: SPECTROPHOTOMETRY, JENDRASSIK & GROFF	DIAZOTIZATION		
BILIRUBIN, INDIRECT	0.36	0.0 - 0.9	mg/dL
METHOD: CALCULATED PARAMETER			
TOTAL PROTEIN	8.7 High	6.0 - 8.0	g/dL



Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist



Dr. Deepak Sanghavi, M.D(Path) (Reg.no.MMC2004/03/1530) Chief of Mumbai Reference Lab.





Page 13 Of 27

View Details

View Repor

# PERFORMED AT :

Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India







PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF

ACCESSION NO: **0002XB029468** AGE/SEX: 35 Years Female

602 b, behind dindoshi depot, dindoshi, malad east

Mumbai 400097 CLIENT PATIENT ID: ABHA NO :

DRAWN :19/02/2024 08:44:16
RECEIVED :19/02/2024 08:45:41
REPORTED :20/02/2024 17:54:14

	İ		
Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
METHOD: SPECTROPHOTOMETRY, COLORIMETRIC-BIURET, REAGE	NT BLANK, SERUM BLANK		
ALBUMIN	4.6	3.97 - 4.94	g/dL
METHOD: SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - D	YE BINDING		
GLOBULIN	4.1 High	2.0 - 3.5	g/dL
METHOD: CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.1	1.0 - 2.1	RATIO
METHOD: CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	26	Upto 32	U/L
METHOD: SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHAT	E ACTIVATION( P5P) - IFCC		
ALANINE AMINOTRANSFERASE (ALT/SGPT)	32	Upto 33	U/L
METHOD: SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHAT	E ACTIVATION( P5P) - IFCC		
ALKALINE PHOSPHATASE	141 High	35 - 104	U/L
METHOD: SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC			
GAMMA GLUTAMYL TRANSFERASE (GGT)	119 High	< 40	U/L
METHOD: SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - G-C	GLUTAMYL-CARBOXY-NITROANIL	IDE - IFCC	
LACTATE DEHYDROGENASE	140	< 223	U/L
METHOD: SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - UV-IFCO			
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	13	6 - 20	mg/dL
METHOD : SPECTROPHOTOMETRY, UREASE -COLORIMETRIC			

METHOD: SPECTROPHOTOMETRY, UREASE -COLORIMETRIC

Dama

Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist



Dr. Deepak Sanghavi,M.D(Path) (Reg.no.MMC2004/03/1530) Chief of Mumbai Reference Lab.





Page 14 Of 27

View Details

View Report



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India Tel: 9111591115, Fax:





AGE/SEX



Female

PATIENT NAME: LIPIKA MISHRA

602 b, behind dindoshi depot, dindoshi, malad east

**REF. DOCTOR:** SELF

ACCESSION NO: 0002XB029468

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO : DRAWN :19/02/2024 08:44:16
RECEIVED :19/02/2024 08:45:41
REPORTED :20/02/2024 17:54:14


:35 Years

Test Report Status Final

Mumbai 400097

**Results** 

**Biological Reference Interval Units** 



CREATININE, SERUM

CREATININE 0.76 0.60 - 1.10 mg/dL

METHOD: SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE KINETIC - RATE BLANKED - IFCC-IDMS STANDARIZED

Dama

Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist Ds/.

Dr. Deepak Sanghavi,M.D(Path) (Reg.no.MMC2004/03/1530) Chief of Mumbai Reference Lab.



Page 15 Of 27

View Details

View Report



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India



602 b, behind dindoshi depot, dindoshi, malad east






PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF

ACCESSION NO: **0002XB029468** AGE/SEX: 35 Years Female

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO : DRAWN :19/02/2024 08:44:16 RECEIVED :19/02/2024 08:45:41 REPORTED :20/02/2024 17:54:14

Test Report Status <u>Final</u> Results Biological Reference Interval Units



**BUN/CREAT RATIO** 

BUN/CREAT RAΠΟ **17.11 High** 8 - 15

METHOD : CALCULATED PARAMETER

URIC ACID, SERUM

URIC ACID 4.9 2.4 - 5.7 mg/dL

METHOD: SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC- URICASE

**TOTAL PROTEIN, SERUM** 

TOTAL PROTEIN **8.7 High** 6.0 - 8.0 g/dL

 ${\tt METHOD}: {\tt SPECTROPHOTOMETRY}, {\tt COLORIMETRIC} \cdot {\tt BIURET}, {\tt REAGENT} \; {\tt BLANK}, {\tt SERUM} \; {\tt BLANK}$ 

**ALBUMIN, SERUM** 

ALBUMIN 4.6 3.97 - 4.94 g/dL

METHOD: SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DYE BINDING

# **GLOBULIN**

Dame

Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist Ds/.

Dr. Deepak Sanghavi, M.D(Path) (Reg.no.MMC2004/03/1530) Chief of Mumbai Reference Lab.





Ellat grade -- AP.

View Report

Page 16 Of 27



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India







**PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF** 

> ACCESSION NO: 0002XB029468 AGE/SEX :35 Years

PATIENT ID : LIPIF17128827 602 b, behind dindoshi depot, dindoshi, malad east

CLIENT PATIENT ID: Mumbai 400097 ABHA NO

:19/02/2024 08:44:16 RECEIVED: 19/02/2024 08:45:41 REPORTED :20/02/2024 17:54:14

	i	i	
Test Report Status <u>Final</u>	Results	Biological Referenc	e Interval Units
GLOBULIN METHOD: CALCULATED PARAMETER	4.1 High	2.0 - 3.5	g/dL
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	137	136 - 145	mmol/L
METHOD : ISE INDIRECT	4.60	25 54	
POTASSIUM, SERUM METHOD: ISE INDIRECT	4.60	3.5 - 5.1	mmol/L
CHLORIDE, SERUM	100	98 - 106	mmol/L
METHOD : ISE INDIRECT			

# Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF,cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake,prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy, adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosi
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia), alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors,	periodic paralysis,trauma	nephropathy, porphyria, expansion of
chlorpropamide,carbamazepine,anti	(transient). Drugs: Adrenergic agents,	extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
		laxative,corticosteroids, diuretics.
Increased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
(excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA, dehydration,
vomiting or diarrhea), diabetes	acidosis, dehydration, renal failure,	overtreatment with
mellitus, diabetesinsipidus,	Addison' s disease, RTA type IV,	saline,hyperparathyroidism, diabetes
hyperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
licorice, oral contraceptives.	potassium- sparing diuretics, NSAIDs,	alkalosis,hyperadrenocorticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide,androgens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignance
	levels are normal.	(Normal serum chloride)

Interpretation(s)
GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the



Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) **Consultant Pathologist** 



Dr. Deepak Sanghavi, M.D (Path) (Reg.no.MMC2004/03/1530) Chief of Mumbai Reference Lab.





Page 17 Of 27

View Report



Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062 Maharashtra, India



602 b, behind dindoshi depot, dindoshi, malad east



AGE/SEX



Female

**REF. DOCTOR: SELF PATIENT NAME: LIPIKA MISHRA** 

ACCESSION NO: 0002XB029468

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO

:19/02/2024 08:44:16 DRAWN RECEIVED: 19/02/2024 08:45:41

:35 Years

REPORTED :20/02/2024 17:54:14

**Test Report Status** Results **Biological Reference Interval Final** Units

Increased in:Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. **Decreased in**: Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol;sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

**NOTE:** While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment,Renal Glyosuria,Glycaemic index & response to food consumed,Alimentary Hypoglycemia,Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

**Bilirubin** is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjuga may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

**ALP** is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease. **GGT** is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain

and seminal vésicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

**Total Protein** also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) **Causes of decreased** level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic

syndrome **Causes of decreased levels**-Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin. **Higher-than-normal levels may be due to:** Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma,Waldenstroms disease. **Lower-than-normal levels may be due to:** Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome,Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) **Consultant Pathologist** 



Dr. Deepak Sanghavi, M.D (Path) (Reg.no.MMC2004/03/1530) Chief of Mumbai Reference Lab.





Page 18 Of 27

View Report



Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

CIN - U74899PB1995PLC045956



Maharashtra, India Tel: 9111591115, Fax:



AGE/SEX



Female

PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF

ACCESSION NO: 0002XB029468

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO : DRAWN :19/02/2024 08:44:16
RECEIVED :19/02/2024 08:45:41
REPORTED :20/02/2024 17:54:14

:35 Years

Test Report Status <u>Final</u> Results Biological Reference Interval Units

#### **CLINICAL PATH - URINALYSIS**

# MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

APPEARANCE CLEAR

602 b, behind dindoshi depot, dindoshi, malad east

# **CHEMICAL EXAMINATION, URINE**

PH	6.0	4.6 - 8.0
SPECIFIC GRAVITY	1.025	1.003 - 1.035
PROTEIN	NOT DETECTED	NOT DETECTED
GLUCOSE	NOT DETECTED	NOT DETECTED
KETONES	NOT DETECTED	NOT DETECTED
BLOOD	NOT DETECTED	NOT DETECTED
BILIRUBIN	NOT DETECTED	NOT DETECTED
UROBILINOGEN	NOT DETECTED	
NITRITE	NOT DETECTED	NOT DETECTED
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED

# MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	0-1	0-5	/HPF
EPITHELIAL CELLS	1-2	0-5	/HPF

CASTS NOT DETECTED CRYSTALS NOT DETECTED

BACTERIA NOT DETECTED NOT DETECTED
YEAST NOT DETECTED NOT DETECTED

METHOD: URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEGRATED AUTOMATED SYSTEM. (PH-DOUBLE INDICATOR,SP. GRAVITY-IONIC CONCEN,GLUCOSE-GOD/POD,PROTEIN- ERROR OF INDICATORS,KETONE-LEGAL'S,BLOOD- PEROXIDASE ACTIVITY-HB,BILIRUBIN-DIAZOTIZATION,UROBILINOGEN-DIAZOTIZATION,NITRITE-GRIESS,LEUKOCYTES- ESTERASES ACTIVITY)

D.S/.

Dr. Deepak Sanghavi,M.D(Path) (Reg.no.MMC2004/03/1530) Chief of Mumbai Reference Lab.



Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist





Page 19 Of 27

View Details

View Report



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India



602 b, behind dindoshi depot, dindoshi, malad east



AGE/SEX



Female

PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF

ACCESSION NO: 0002XB029468

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO : DRAWN :19/02/2024 08:44:16 RECEIVED :19/02/2024 08:45:41

:35 Years

REPORTED :20/02/2024 17:54:14

Test Report Status Final Results Biological Reference Interval Units

# Interpretation(s)

Mumbai 400097

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
0 1 0	
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

D.S/.

Dr. Deepak Sanghavi,M.D(Path) (Reg.no.MMC2004/03/1530) Chief of Mumbai Reference Lab. Damo

Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist



Page 20 Of 27

View Details

View Report



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India







PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF

ACCESSION NO: **0002XB029468** AGE/SEX

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO : DRAWN :19/02/2024 08:44:16
RECEIVED :19/02/2024 08:45:41
REPORTED :20/02/2024 17:54:14

:35 Years

Test Report Status <u>Final</u> Results Biological Reference Interval Units

## **CYTOLOGY**

#### MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

602 b, behind dindoshi depot, dindoshi, malad east

**PAPANICOLAOU SMEAR** 

Mumbai 400097

TEST METHOD CONVENTIONAL GYNEC CYTOLOGY

SPECIMEN TYPE TWO UNSTAINED CERVICAL SMEARS RECEIVED

2CX-4804

REPORTING SYSTEM 2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY

SPECIMEN ADEQUACY SMEARS ARE SATISFACTORY FOR EVALUATION.

MICROSCOPY THE SMEARS SHOW MAINLY INTERMEDIATE SQUAMOUS CELLS, FEW

SUPERFICIAL SQUAMOUS CELLS IN THE MODERATE BACKGROUND OF

POLYMORPHS.

INTERPRETATION / RESULT NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY

REACTIVE CELLULAR CHANGES ASSOCIATED WITH INFLAMMATION

(INCLUDES TYPICAL REPAIR - MODERATE INFLAMMATION).

# Comments

Suggestions / Guidelines: (REF: THE BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY,2014, 3rd Edition) ADVISED REPEAT SMEAR, AFTER TREATMENT OF INFLAMMATION.

- 1) Please note papanicolaou smear study is a screening procedure for cervical cancer with inherent false negative results, hence should be interpreted with caution.
- 2) No cytologic evidence of hpv infection in the smears studied.
- 3) Primary screening of papanicolaou smears is carried out by cytotechnologist with 100% rescreening and reporting by surgical pathologist.

Dr.Nidhi Garg,MD (Reg.No.MMC 2009/09/3278) Histopathologist



Page 21 Of 27

/iew Details

View Report









**PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF** 

> ACCESSION NO: 0002XB029468 AGE/SEX :35 Years

602 b, behind dindoshi depot, dindoshi, malad east

Mumbai 400097

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO

DRAWN :19/02/2024 08:44:16 RECEIVED: 19/02/2024 08:45:41

REPORTED :20/02/2024 17:54:14

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

# **CLINICAL PATH - STOOL ANALYSIS**

# MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, STOOL

**COLOUR BROWN** 

CONSISTENCY SEMI FORMED

**MUCUS** NOT DETECTED NOT DETECTED

VISIBLE BLOOD **ABSENT ABSENT** 

ADULT PARASITE NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

**CHEMICAL EXAMINATION, STOOL** 

STOOL PH 6.0

OCCULT BLOOD NOT DETECTED NOT DETECTED

METHOD: MODIFIED GUAIAC METHOD

MICROSCOPIC EXAMINATION, STOOL

NOT DETECTED /hpf **PUS CELLS** 

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED NOT DETECTED /HPF RED BLOOD CELLS

NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED NOT DETECTED **CYSTS** 

METHOD: MICROSCOPIC EXAMINATION

METHOD: MICROSCOPIC EXAMINATION

**LARVAE** NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION **TROPHOZOITES NOT DETECTED** NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

**ABSENT FAT** 

CHARCOT LEYDEN CRYSTALS **ABSENT** 



OVA

Dr. Ekta Patil, MD (Reg.No. MMC2008/04/1142) Senior Microbiologist





Page 22 Of 27

View Report





602 b, behind dindoshi depot, dindoshi, malad east



AGE/SEX



Female

**PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF** 

ACCESSION NO: 0002XB029468

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO

:19/02/2024 08:44:16 RECEIVED: 19/02/2024 08:45:41 REPORTED :20/02/2024 17:54:14

:35 Years

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

## Interpretation(s)

Mumbai 400097

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION
Pus cells	Pus in the stool is an indication of infection
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.
Charcot-Leyden crystal	Parasitic diseases.
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.
Frank blood	Bleeding in the rectum or colon.
Occult blood	Occult blood indicates upper GI bleeding.
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.
рН	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.

# ADDITIONAL STOOL TESTS:

- Stool Culture: This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if 1. treatment for GI infection worked.
- Fecal Calprotectin: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) 2. from Irritable Bowel Syndrome (IBS).
- 3. Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia.
- Clostridium Difficile Toxin Assay: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.
- 5. Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array Test, (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus ,parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.

Dr. Ekta Patil, MD (Reg.No. MMC2008/04/1142) Senior Microbiologist





Page 23 Of 27

View Report



Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062

CIN - U74899PB1995PLC045956



602 b, behind dindoshi depot, dindoshi, malad east



AGE/SEX



Female

PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF

ACCESSION NO: 0002XB029468

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO : DRAWN :19/02/2024 08:44:16
RECEIVED :19/02/2024 08:45:41
REPORTED :20/02/2024 17:54:14

:35 Years

Test Report Status <u>Final</u> Results Biological Reference Interval Units

6. <u>Rota Virus Immunoassav</u>: This test is recommended in severe gastroenteritis in infants & children associated with watery diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.

事81

Dr. Ekta Patil,MD (Reg.No. MMC2008/04/1142) Senior Microbiologist





Page 24 Of 27

View Details

View Report



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India







PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF

ACCESSION NO: 0002XB029468 AGE/SEX:35 Years

602 b, behind dindoshi depot, dindoshi, malad east

Mumbai 400097

ABHA NO :

: LIPIF17128827 DRAWN :19/02/2024 08:44:16
TID: RECEIVED :19/02/2024 08:45:41
: REPORTED :20/02/2024 17:54:14

Test Report Status <u>Final</u> Results Biological Reference Interval Units

# **SPECIALISED CHEMISTRY - HORMONE**

# MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE THYROID PANEL, SERUM

T3 132.0 Non-Pregnant Women ng/dL

80.0 - 200.0 Pregnant Women

1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0

METHOD: COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY

T4 10.50 Non-Pregnant Women µg/dL

5.10 - 14.10 Pregnant Women

1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70

3rd Trimester: 6.95 - 15.70 METHOD: COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY

TSH (ULTRASENSITIVE) 2.430 NonPregnant Women 0.27- µIU/mL

4.20

Pregnant Women (As per American Thyroid Association) 1st Trimester 0.100 - 2.500 2nd Trimester 0.200 - 3.000 3rd Trimester 0.300 - 3.000

METHOD: SANDWICH ELECTROCHEMILUMINESCENCE IMMUNOASSAY

# Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically

D.S/.

Dr. Deepak Sanghavi, M.D(Path) (Reg.no.MMC2004/03/1530) Chief of Mumbai Reference Lab.



Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist





Page 25 Of 27

iew Details

View Report



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India



602 b, behind dindoshi depot, dindoshi, malad east





Female

PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF

ACCESSION NO: 0002XB029468 AGE/SEX

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO : DRAWN :19/02/2024 08:44:16
RECEIVED :19/02/2024 08:45:41

:35 Years

REPORTED :20/02/2024 17:54:14

Test Report Status <u>Final</u> Results Biological Reference Interval Units

active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011.

# TSH in pregnancy

There's reduction in both the lower and the upper limit of maternal TSH relative to the non-pregnant TSH reference range. This is because of elevated levels of serum hCG that directly stimulates the TSH receptor, thereby increasing thyroid hormone production. The largest decrease in serum TSH is observed during the first trimester. Thereafter, serum TSH and its reference range gradually increases in the second and third trimesters, but nonetheless remains lower than in non-pregnant women.

NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

\*\*End Of Report\*\*
Please visit www.agilusdiagnostics.com for related Test Information for this accession

D.S/.

Dr. Deepak Sanghavi, M.D(Path) (Reg.no.MMC2004/03/1530) Chief of Mumbai Reference Lab. Dama

Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist





Page 26 Of 27

View Details

View Report



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India





AGE/SEX



Female

PATIENT NAME: LIPIKA MISHRA REF. DOCTOR: SELF

ACCESSION NO: 0002XB029468

PATIENT ID : LIPIF17128827

CLIENT PATIENT ID: ABHA NO : DRAWN :19/02/2024 08:44:16

RECEIVED :19/02/2024 08:45:41

REPORTED :20/02/2024 17:54:14

:35 Years

Test Report Status <u>Final</u> Results Biological Reference Interval Units

# **CONDITIONS OF LABORATORY TESTING & REPORTING**

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.

602 b, behind dindoshi depot, dindoshi, malad east

- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
  - i. Specimen received is insufficient or inappropriate
  - ii. Specimen quality is unsatisfactory
  - iii. Incorrect specimen type
  - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

**Agilus Diagnostics Limited** 

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

85%.

Dr. Deepak Sanghavi,M.D(Path) (Reg.no.MMC2004/03/1530) Chief of Mumbai Reference Lab.



Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist





Page 27 Of 27

View Details

View Report



Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India

